Stock ARDS ARIDIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Market Closed - OTC Markets
Other stock markets
 20:39:49 01/05/2024 BST 		5-day change 1st Jan Change
0.0588 USD -2.08% Intraday chart for Aridis Pharmaceuticals, Inc. -7.40% -16.12%
2023 Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023. CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Sector Update: Health Care Stocks Steady Premarket Tuesday
Aridis Pharmaceuticals, European Regulator Agree on Pneumonia Phase 3 Study Parameters; Shares Jump Premarket
Aridis Pharmaceuticals Reaches Agreement for Phase 3 Study of Pneumonia Treatment in Europe; Shares Jump After Hours
Aridis Receives Agreement from the European Medicines Agency on the Clinical Study Design and A Single Confirmatory Phase 3 Study of AR-301
Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product Designation
Aridis Pharmaceuticals' AR-301 Eligible for Consideration Under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Sector Update: Health Care Stocks Advancing Late Wednesday
Sector Update: Health Care
Top Midday Gainers
Aridis Pharmaceuticals, Inc. Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Aridis Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
Aridis Pharmaceuticals, Inc. Terminates License, Development and Commercialization Agreement with Serum
Aridis Pharmaceuticals, Inc. Announces the Resignation of Robert Ruffolo as Director
Aridis Pharmaceuticals Launching $2.28 Million Stock Offering; Shares Drop
Aridis Pharmaceuticals Says Phase 2a Cystic Fibrosis Trial Meets Targets; Shares Jump
Aridis Pharmaceuticals, Inc. Meets Primary and Secondary Endpoints in Phase 2A Study of AR-501 in Cystic Fibrosis Patients
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARDS Stock
  4. News Aridis Pharmaceuticals, Inc.
  5. Other languages